Publications by authors named "Shiying Niu"
Background: Radiotherapy has become a standard treatment for chest tumors, but a common complication of radiotherapy is radiation lung injury. Currently, there is still a lack of effective treatment for radiation lung injury.
Methods: A mouse model of radioactive lung injury (RILI) was constructed and then treated with different cycles of hydrogen inhalation.
Article Synopsis
- Radiation pneumonitis (RP) is a common issue for lung cancer patients undergoing radiation therapy, with no existing effective treatments to improve outcomes.
- The study explores the role of angiotensin-converting enzyme 2 (ACE2) in RP, finding that enhancing ACE2 expression can reduce lung injury in mice and that specific medications (captopril and valsartan) activate ACE2 and lessen RP effects.
- A review of patients showed that those taking renin-angiotensin system inhibitors (RASis) experienced significantly lower rates of RP compared to those not on these medications, indicating potential for RASis as new treatment options for RP.
Radiation-induced lung injury (RILI) is a common complication of radiotherapy for thoracic tumor. Its incidence rate is as high as 20%. At present, there is no effective treatment in clinical practice.
View Article and Find Full Text PDFRadiation-induced lung injury (RILI) is one of the most common complications associated with radiotherapy, characterized by early-stage radiation pneumonia and subsequent radiation pulmonary fibrosis. However, effective therapeutic strategies for RILI are currently lacking. Recently, an increasing number of studies reported that mesenchymal stem cells (MSCs) can enhance the regeneration of damaged tissue, modulate the inflammatory response, reduce the levels of fibrotic cytokines and reactive oxygen species, and inhibit epithelial-mesenchymal transformation.
View Article and Find Full Text PDF